2012 Fiscal Year Final Research Report

Novel cancer therapy using Bisabolol and modified Bisabolol

Research Project

Project/Area Number	22791273
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Digestive surgery
Research Institution	Nagoya University
Principal Investigator	ITATSU Keita 名古屋大学, 医学系研究科, 寄附講座助教 (90534842)
Project Period (FY)	2010 – 2012
Keywords	ビサボロール / 胆管癌 / PI3K-AKT シグナル
Research Abstract	We investigated whether Bisabolol has antitumor effects against these cancers. Bisabolol induced a decrease in cell proliferation and viability in cholangiocarcinoma and pancreatic cancer cell lines, but not in pancreatic epithelial cells. Profiling revealed that treatment induced apoptosis and suppressed Akt activation in cholangiocarcinoma. Bisabolol treatment induced the overexpression of early growth response-1 (EGR1). Furthermore, Tumor growth in both subcutaneous and peritoneal xenograft nude mouse models was significantly inhibited by intragastric administration of 1000 mg/kg of Bisabolol, once a week for three weeks. The results indicate thatBisabolol could be a novel therapeutic option for the treatment of cholangiocarcinoma and pancreatic cancer.